Equillium to Present at Investor Conferences in November 2020
November 10 2020 - 8:35AM
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company developing itolizumab to treat severe autoimmune and
inflammatory disorders, today announced that Bruce Steel,
Equillium’s chief executive officer and Krishna Polu, M.D.,
Equillium’s chief medical officer, will present at two upcoming
investor conferences in November 2020.
Event: Date:
Time:Location: |
Stifel 2020 Virtual Healthcare ConferenceWednesday, November 18,
20203:20 PM Eastern Time | 12:20 PM Pacific TimeVirtual
Webcast |
|
|
Event: Date:
Time:Location: |
Jefferies Virtual London Healthcare ConferenceThursday, November
19, 20206:10 PM GMT | 1:10 PM Eastern Time | 10:10 AM PM Pacific
TimeVirtual Webcast |
Live webcasts of both presentations will be
available under the “Investors” section of the Company’s website at
https://ir.equilliumbio.com/. Replays will be available for 30 days
following each webcast.
About ItolizumabItolizumab is a clinical-stage,
first-in-class monoclonal antibody that selectively targets the
CD6-ALCAM pathway. This pathway plays a central role in modulating
the activity and trafficking of T cells that drive a number of
immuno-inflammatory diseases. Itolizumab is currently being
evaluated in multiple clinical trials in patients with severe
diseases, including aGVHD, lupus nephritis, uncontrolled asthma,
and will soon be evaluated in a clinical trial of patients with
COVID-19. Equillium acquired rights to itolizumab through an
exclusive partnership with Biocon Limited. Itolizumab is marketed
in India under the trade name “ALZUMAb-L” for the treatment of
chronic plaque psoriasis and has received emergency use approval in
India to treat cytokine release syndrome in COVID-19 patients with
moderate to severe acute respiratory distress syndrome.
About EquilliumEquillium is a clinical-stage
biotechnology company leveraging deep understanding of
immunobiology to develop novel products to treat severe autoimmune
and inflammatory disorders with high unmet medical need. Equillium
is developing itolizumab for multiple severe immuno-inflammatory
diseases, including COVID-19, aGVHD, lupus nephritis and
uncontrolled asthma.
For more information,
visit www.equilliumbio.com.
Investor Contact
Christine Zedelmayer, Chief Operating
Officer+1-858-412-5302ir@equilliumbio.com
Media Contact
Katherine Carlyle SmithSenior Account
AssociateCanale Communications+1-805-907-2497
katherine.smith@canalecomm.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024